; (B) hold public meetings to elicit input from stakeholders on the proposal; and (C) not later than 180 days after the Secretary’s receipt of the proposal, publish a final version of the list. (5) Subsequent updates The Secretary, in coordination with the Committee, shall revise, and publish in accordance with paragraph (4), the list of critical need antimicrobial priorities within 30 days of approval of a product designated under subsection (k) or if the Secretary determines it is necessary, but in any case no later than every 2 years. (6) Restriction on removal from list No critical need antimicrobial priority may be removed from the list of critical need antimicrobial priorities until after submission of the report required by subsection (n)(1). (k) Designation of priority antimicrobial products (1) Request The manufacturer or sponsor of a drug may request that the Secretary designate a drug as a priority antimicrobial product at any time before or after submission of an application for approval or licensure of such drug under section 505(b) of this Act or section 351(a) of the Public Health Service Act, as applicable. (2) Designation Not later than 60 days after the submission of a request under paragraph (1), the Secretary, in coordination with the Committee, shall— (A) (i) approve the request if the drug subject to the request is intended to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen that is listed as a critical need antimicrobial priority pursuant to subsection (j); or (ii) disapprove the request if the drug subject to the request is not intended to treat or prevent such a disease